Aurobindo Pharma Ltd. has announced that its wholly-owned subsidiary, Eugia Pharma Specialities Ltd., has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. The product is expected to be launched in Q1 FY26.

The Tablet is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, of Bristol-Myers Squibb Company (BMS).

The approved product has an estimated market size of USD 1.8 billion for the twelve months ending February 2025, according to IQVIA MAT.

This is the 181st ANDA approval (including 9 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products.

Dasatinib Tablets is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib and adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.